AiCure

Global News

Lexicon expands management

Thursday, November 6, 2014 03:13 PM

Lexicon Pharmaceuticals has announced management additions directed toward the completion of phase III development and commercial preparations for telotristat etiprate in carcinoid syndrome and preparation for phase III initiation and commercial readiness for sotagliflozin (LX4211) in type 1 diabetes.

More... »


Study: Large enterprises view business transformation as essential

Thursday, November 6, 2014 12:41 PM

Continual business transformation is crucial for companies to stay ahead of emerging players and maintain a competitive edge. From bringing new offerings to market to deploying IT systems to major capital expenditures, business transformation can take countless forms. Many large institutions, however, are struggling with their transformation efforts, according to a study from Oracle, a multinational computer technology corporation headquartered in Redwood City, Calif., and Forbes.

More... »


Takara Bio selects Genedata software to automate, standardize NGS data analysis

Thursday, November 6, 2014 12:35 PM

Takara Bio, a global biotechnology company based in Shiga, Japan, has chosen Genedata Expressionist for Genomic Profiling as its key software platform for next-generation sequencing (NGS) data. Genedata, headquartered in Switzerland, is a provider of advanced software solutions for drug discovery and life science research.

More... »

DaVita Clinical Research, St. Anthony Hospital collaborate

Wednesday, November 5, 2014 01:57 PM

DaVita Clinical Research (DCR), a Minneapolis, Minn.-based specialty CRO, now can offer its sponsors increased patient access, on-site ancillary services and specialty physician experience in key therapeutic areas through a partnership with St. Anthony Hospital in Lakewood, Colo. 

More... »

MedImmune acquires Definiens, strengthens immuno-oncology capabilities

Wednesday, November 5, 2014 12:55 PM

AstraZeneca’s global biologics R&D arm MedImmune has entered into an agreement to acquire Germany-based Definiens, a privately held company focused on imaging and data analysis technology, known as Tissue Phenomics, which dramatically improves the identification of biomarkers in tumor tissue.

More... »

Proteostasis Therapeutics, Astellas form $1.2B collaboration

Wednesday, November 5, 2014 12:54 PM

Proteostasis Therapeutics, a Cambridge, Mass.-based company developing novel therapeutics to address diseases caused by defects in protein folding, trafficking and clearance, and Astellas Pharma have entered into a worldwide R&D collaboration for therapeutic candidates that modulate the unfolded protein response (UPR) through the use of Proteostasis Therapeutics’ proprietary Disease Relevant Translation (DRT) and Proteostasis Network platform.

More... »

Bristol-Myers Squibb signs option agreement to acquire Galecto Biotech

Wednesday, November 5, 2014 12:50 PM

Bristol-Myers Squibb has entered into an agreement with the exclusive option to acquire Denmark’s Galecto Biotech and gain worldwide rights to its lead asset TD139, a novel inhaled inhibitor of galectin-3 in phase I development for the treatment of idiopathic pulmonary fibrosis (IPF) and other pulmonary fibrotic conditions. Total aggregate payments under the agreement have the potential to reach $444 million, which includes the option fee, an option exercise fee and subsequent clinical and regulatory milestone payments.

More... »

DSG, OPKO Health ink agreement for trial management solution

Wednesday, November 5, 2014 12:50 PM

OPKO Health, a multinational pharmaceutical and diagnostics company, has selected Malvern, Pa.-based DSG’s eCaseLink integrated suite for self-building of harmonized electronic data capture (EDC), IWRS, drug safety event capture and case reporting and CTMS systems. DSG’s team will support the OPKO team and their site users.

More... »

LEO Pharma, Japan Tobacco ink license agreement for JTE-052

Wednesday, November 5, 2014 12:47 PM

LEO Pharma and Japan Tobacco (JT) have entered into a license agreement, under which LEO Pharma will obtain exclusive rights to further develop, register and market JT’s experimental JAK inhibitor, JTE-052, for topical use in dermatological indications worldwide, excluding Japan where JT retains rights.

More... »

Dana-Farber Cancer Institute, Astellas form research collaboration

Wednesday, November 5, 2014 12:45 PM

Dana-Farber Cancer Institute and Astellas Pharma have inked a three-year R&D collaboration for small molecule inhibitors of oncogenic K-Ras for the treatment of cancer, including lung cancer.

More... »

`
CenterWatch Data Library
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

November 24

Tufts CSDD’s $2.6 billion price tag to develop and bring a new drug to market raises questions, criticisms

Medidata joins GlaxoSmithKline in study to evaluate the impact of wearing mobile devices in clinical trials

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

November

Private equity driving dynamic CRO growth
Enables CROs to pursue long-term strategies, while giving the space credibility

Baby boomers poised to reshape clinical trials industry
Millions of tech-savvy consumers already track their health, expect new treatments as they age

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

October

CROs driving changes in patient recruitment
Data- and tech-aided enrollment services a competitive advantage

Trials with in-home nurses poised to grow
Higher expense, but may improve recruitment and retention for select trials

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs